Research Article

Association of HER1 and HER2 Gene Variants in the Predisposition of Colorectal Cancer

Ibrahim O. Alanazi,1,2 Jilani Purusottapatnam Shaik,2 Nasirima Reddy Parine,2 Nahla A. Azzam,3,4 Othman Alharbi,3,4 Yousef M. Hawsawi,5,6 Atif Abdulwahab A. Oyouni,7,8 Osama M. Al-Amer,8,9 Faisal Alzahrani,8,10 Majid A. Almadi,3,4 Abdulrahman M. Aljebreen,3,4 Mohammad Saud Alanazi,2 and Zahid Khan2

1. Introduction

Colorectal cancer (CRC) is one of the leading causes of cancer-related mortality and morbidity around the world [1]. As per gender segregation, it is the third commonly diagnosed cancer in men and ranks second in women [2]. In 2018, the estimated total number of new cases was 1,849,518 while the number of deaths was 880,792 [3].
and mortality of CRC in men are approximately 20% higher than in women. In Saudi Arabia, both the genders combined, CRC is the second most common cancer with an estimated incidence of 3564 (14.6%) cases and mortality of 1603 (15.2%) in the year 2018 [3].

Colorectal tumorigenesis is a multistep process involving accumulation of mutations in oncogenes and tumor suppressor genes leading to the sequential transformation of the colorectal normal epithelium to adenoma followed by invasive and metastatic tumor [4]. Various risk factors including ethnicity, environment, and genetics have been attributed towards the predisposition of CRC [5]. SNPs are considered to be the main source of genetic variation which accounts for about 90 percent of all human genetic variations occurring roughly every 100–300 bases [6]. Most SNPs are usually located in noncoding regions, and their distribution is not under selective pressure [7]. However, SNPs occurring in coding sequences of genes may lead to protein expression changes that directly contribute to a disease phenotype [8]. The location of these SNPs near genes that are involved in a crucial role such as gene expression and regulation, signal transduction, and the control of cell cycle may affect the function of such genes. An important molecular mechanism involved in the development and the progression of CRC is the mitogen-activated protein kinase (MAPK) cascade downstream of the epidermal growth factor receptor (EGFR) [9].

The EGFR also known as human epidermal growth factor receptor 1 (HER1) belongs to the ErbB family of transmembrane protein receptors that function as a receptor tyrosine kinase (RTK). The ErbB family consists of four members including ErbB-1 (HER1/EGFR), ErbB-2 (HER2), ErbB-3 (HER3), and ErbB-4 (HER4) [9]. Previous studies have reported that HER1 and HER2 gene polymorphisms are associated with several malignancies such as colon [10], breast [11, 12], and lung cancers [13]. Additionally, HER2 polymorphism has also been linked with higher expression of the protein in breast and ovarian cancers [14, 15].

Large efforts are being made in identifying trustworthy biomarkers for early detection of human malignant cancers. Genetic variation analysis such as SNPs can be used for predicting novel diagnostic and prognostic genetic markers. In this study, we examine the effect of four SNPs, rs763317 and rs3752651 located in HER1 and rs1058808 and rs1136201 located in HER2, on CRC susceptibility in Saudi Arabian patients by comparing the genotypic and allelic distribution of these SNPs in cancer cases to that of healthy subjects.

2. Materials and Methods

2.1. Sampling and DNA Isolation. Colorectal cancer patients (n = 143) included all ages (median age = 58 years) and histopathologically confirmed cases of the disease. Approximately 3 ml of blood samples from colorectal cancer patients attending the endoscopy department of King Khalid University Hospital, King Saud University, was collected in ethylenediaminetetraacetic acid (EDTA-) containing vacutainers prior to therapy. Additionally, age- and gender-matched normal subjects with no history of cancer were recruited as controls. The study was reviewed and approved by the institutional review board of College of Medicine, King Saud University (Project approval No. E-12-596). Written informed consent was obtained from all the patients. Genomic DNA was isolated from peripheral blood cells using the QIAmp DNA blood mini kit (Qiagen, USA) according to manufacturer’s instructions. Quantitation and purity of DNA were examined on a NanoDrop 8000 spectrophotometer (Thermo Scientific, USA).

2.2. Genotyping. Based on previous studies, four SNPs in HER1, rs763317 and rs3752651, and HER2, rs1058808 and rs1136201, were selected for this study [10, 16–19]. TaqMan allelic discrimination assays (Thermo Fisher Scientific, USA) were used for genotyping colorectal cancer and control peripheral blood DNA samples for these SNPs. The TaqMan assay ID and number of samples for which genotype calls were obtained for each SNP are as follows: rs763317 (assay ID = C____2310200_10, cancer = 140, control = 149), rs3752651 (assay ID = C____326500_10, cancer = 143, control = 163), rs1058808 (assay ID = C____1551672_20, cancer = 139, control = 160), and rs1136201 (assay ID = C____7452451_1, cancer = 141, control = 162). Each reaction contained 20 ng of DNA, 5.0 μL of 2X TaqMan genotyping Master Mix (Applied Biosystems, USA), and 0.25 μL of 40X TaqMan assay in a total volume of 10 μL. Genotyping experiments were conducted by endpoint reading on the QuantStudio 7 Flex Real-Time PCR machine (Applied Biosystems, USA), and genotype calls were made by TaqMan Genotyper Software version 1.6.

2.3. Statistical Analyses. Genotype and allele frequencies of polymorphic variants examined in HER1 and HER2 genes were determined, and tests for association and Hardy–Weinberg equilibrium were performed on a web-based tool at https://ihg.helmholtz-muenchen.de/cgi-bin/hw/hwa1.pl. For each SNP, odds ratios, confidence intervals, chi-square, and significance were calculated to assess the existence of an association between the SNP and colorectal cancer. Statistical significance was kept at a p value of ≤0.05. Bonferroni correction was used for multiple comparison with an α = 0.0125 considered as significant.

3. Results

In the present study, the genotypes of four germline SNPs residing in HER1, rs763317 and rs3752651, and HER2, rs1058808 and rs1136201, were evaluated in order to determine their association with colorectal cancer risk in Saudi Arabian population. The rs763317 and rs3752651 are located in the intron of HER1, whereas the rs1058808 (P1170A) and rs1136201 (Ile655Val) are nonsynonymous coding SNPs in HER2.

The distribution of genotypes of these SNPs in both the control and cancer groups was examined for Hardy–Weinberg equilibrium (HWE). All the SNPs followed Hardy–Weinberg equilibrium except rs3752651 (p = 0.045373)
in cancers (Table 1). A high rate of consanguinity in the Saudi Arabian population could be a probable cause for this lack of Hardy–Weinberg equilibrium [20].

3.1. Association of HER1 and HER2 Variants with Colorectal Cancer Risk. The distributions of genotype and allele frequencies of the chosen SNPs within the HER1 and HER2 genes and their association with colorectal cancer were evaluated between both colorectal cancer patients and healthy individuals (Table 2). The rs3752651 within HER1 showed a statistically significant association with colorectal cancer susceptibility. In the control group, the frequency of the CC genotype of rs3752651 was detected at 4%, whereas none of the colorectal cancer patients harbor this genotype. It was estimated that individuals carrying the CC genotype of rs3752651 had about 11-fold lower risk of developing colorectal cancer compared to those with the TT genotype (OR = 0.090, \( \chi^2 = 5.03, p = 0.02493 \)). Furthermore, the rs1136201 variant in the HER2 gene revealed a significant protective association with CRC. Individuals with the minor allele G of rs1136201 were 80% less likely to develop CRC compared to those having A allele (OR = 0.275, \( \chi^2 = 5.33, p = 0.01746 \)). Additionally, both other two SNPs, rs763317 (HER1) and rs1058808 (HER2), did not show a significant association with the predisposition of colorectal cancer in the overall analysis (Table 2).

3.2. Association of HER1 and HER2 SNPs with Colorectal Cancer Based on the Age of Onset of the Disease. To determine whether HER1 SNPs s763317 and rs3752651 and HER2 SNPs rs1058808 and rs1136201 have any association with the age at colorectal cancer diagnosis, colorectal cancer patients were stratified based on the median age at the time of disease diagnosis as ≤58 and > 58 years, and the genotype and allele frequencies were compared to the age-matched controls. Our data demonstrated that none of the analyzed SNPs had a noticeable association with colorectal cancer suggesting that these variants do not influence early or late onset of the disease (Table 3).

3.3. HER1 and HER2 SNPs’ Association with Colorectal Cancer Risk Based on Gender. We investigated whether gender plays any role in the association of HER1 SNPs, rs3752651 and rs763317, and HER2 SNPs, rs1058808 and rs1136201, with CRC. Our data indicated that the CC genotype of rs3752651 imparts significant protection against CRC only in men (OR = 0.077, \( \chi^2 = 5.60, p = 0.01798 \)). Additionally, both SNPs examined in HER2 showed a significant association with CRC but only in women. The rs1058808 increased the risk while rs1136201 was protectively associated with CRC. For the rs1058808 loci, CC homozygotic women showed approximately 3.8-fold higher risk of developing colorectal cancer compared to those having the GG genotype (OR = 3.875, \( \chi^2 = 5.65, p = 0.01746 \)). According to the allelic model as well, the minor allele C of rs1058808 conferred a significant association with CRC (OR = 1.665, \( \chi^2 = 4.04, p = 0.04439 \)). The minor allele G of rs1136201 SNP in HER2 lowers the susceptibility of developing colorectal cancer in women about 4-fold compared with those having A allele (OR = 0.244, \( \chi^2 = 7.26, p = 0.00705 \)). This association persisted even after Bonferroni correction for multiple comparisons. Moreover, the AG heterozygous women for this SNP also had significant protection against this cancer compared to those with the AA genotype (OR = 0.275, \( \chi^2 = 5.33, p = 0.02093 \)) (Table 4).

4. Discussion

The HER family of receptors are transmembrane tyrosine kinases; they play a key role in the regulation of various cellular functions in response to extracellular signaling. The basic aspect of signaling in the HER family is the interaction of two receptors [21]. When HER family members dimerize, it leads to transphosphorylation of their intracellular domain generating the initial signal that activates several downstream signaling pathways [21]. HER family signaling is deregulated in several cancer types, mainly in breast and lung cancers [11–13].

In the present study, we evaluated the role of SNPs rs763317 and rs3752651 residing in HER1 and rs1058808 and rs1136201 in HER2 genes in colorectal cancer in a Saudi population. Very few studies have examined the association of these SNPs with colorectal cancers. To the best of our knowledge, this is the first study to evaluate the association of HER1 and HER2 gene polymorphism with colorectal cancer risk in a Saudi Arabian population. We have demonstrated that the HER1 SNP rs3752651 and HER2 exonic SNP rs1136201 are protectively associated with colorectal cancer in the overall analysis. Additionally, gender segregation of the population revealed that the association with CRC was statistically significant in men for rs3752651 and women for rs1136201. While the CC genotype of rs3752651 provided significantly increased protection (OR = 0.077, \( p = 0.01798 \)) relative to the TT genotype in men, such association was not observed in women. Contrary to our finding of protective association in the overall analysis (OR = 0.090, \( p = 0.024 \)), Poole et al. demonstrated that the CC genotype of rs3752651 conferred 40% increased risk of colon cancer relative to those having the TT genotype. However, this association was not statistically significant for rectal cancer as well as when the cases were pooled together as colorectal cancers [10]. In glioma patients, the CC genotype of rs3752651 was found to be significantly associated with decreased overall and progression-free survival compared to the TT genotype [22].

Contradictory results pertaining to the association of rs1136201 in HER2 with various malignancies exist. While in the overall analysis of our population, the genotypes of rs1136201 were not associated with colorectal cancers, we observed a protective association with the G allele conferring 1.8-fold lower risk of developing the disease relative to the A allele. Similar to our findings, the genotypic analysis of rs1136201 in the Indian as well as Scottish Caucasian population did not show a significant correlation with colorectal carcinoma [17, 18]. Interestingly, when our population were segregated based on gender, the rs1136201
demonstrated that women carriers of the AG genotype and the G allele were at 3.6-fold (OR = 0.275, \( p = 0.02093 \)) and 4.1-fold (OR = 0.244, \( p = 0.00705 \)) lower risk of colorectal malignancy relative to the AA genotype and A allele, respectively. Similar to our findings, de Almeida et al. reported a negative association in a dominant model of analysis comparing AG + GG versus AA as well as G allele with breast cancer in a Brazilian population [23]. Additionally, Nelson et al. in a United States population from Wisconsin suggested an inverse relationship of the GG genotype of rs1136201 withinvasive breast cancer. His inverse association was stronger in women aged more than 55 years, those without a family history of breast cancer, postmenopausal women with higher body mass index, and cases with regional or distant metastasis [24]. Few investigations tried to address the functional consequence of A or G allele of rs1136201 with HER2 protein overexpression. Millikan et al. found that breast tumors from women that possess the GG genotype displayed higher expression of HER2, but the results did not reach statistical significance [14]. In ovarian cancer patients from a South Indian state of Tamil Nadu, Shanmugapriya et al. demonstrated that the GG homozygotes of rs1136201 strongly expressed HER2 protein [15]. A similar association of the GG genotype and HER2 protein overexpression as well as patient survival was not observed in colorectal cancer patients [18].

| SNP ID  | Genotype | Controls, \( n \) (frequency) | HWE \( p \) value | Cancer, \( n \) (frequency) | HWE \( p \) value |
|--------|----------|-------------------------------|----------------|----------------------------|----------------|
| rs763317 | AA       | 43 (0.29)                     | 0.146801       | 40 (0.29)                  | 0.538722       |
|         | GA       | 82 (0.55)                     |                | 73 (0.52)                  |                |
|         | GG       | 24 (0.16)                     |                | 27 (0.19)                  |                |
| rs3752651 | TT       | 119 (0.73)                    | 0.191444       | 102 (0.71)                 | 0.045373       |
|         | CT       | 38 (0.23)                     |                | 41 (0.29)                  |                |
|         | CC       | 6 (0.04)                      |                | 0 (0)                      |                |
| rs1058808 | GG       | 62 (0.39)                     | 0.208318       | 44 (0.32)                  | 0.610697       |
|         | CG       | 81 (0.51)                     |                | 71 (0.51)                  |                |
|         | CC       | 17 (0.11)                     |                | 24 (0.17)                  |                |
| rs1136201 | AA       | 123 (0.76)                    | 0.672787       | 120 (0.85)                 | 0.339372       |
|         | AG       | 37 (0.23)                     |                | 21 (0.15)                  |                |
|         | GG       | 2 (0.01)                      |                | 0 (0)                      |                |

HWE, Hardy–Weinberg equilibrium.

| SNP ID  | Genotype | Controls, \( n \) (frequency) | Colorectal cancer, \( n \) (frequency) | OR (95% CI) | \( \chi^2 \) value | \( p^* \) value |
|---------|----------|-------------------------------|----------------------------------------|-------------|-----------------|----------------|
| rs763317 HER1 | AA       | 43 (0.29)                     | 40 (0.29)                              | Ref         |                 |                |
|         | GA       | 82 (0.55)                     | 73 (0.52)                              | 0.957 (0.561–1.632) | 0.03         | 0.87181       |
|         | GG       | 24 (0.16)                     | 27 (0.19)                              | 1.209 (0.602–2.431) | 0.28         | 0.59350       |
|         | A        | 168 (0.56)                    | 153 (0.55)                             | Ref         |                 |                |
|         | G        | 130 (0.44)                    | 127 (0.45)                             | 1.073 (0.773–1.490) | 0.18         | 0.67521       |
| rs3752651 HER1 | TT       | 119 (0.73)                    | 102 (0.71)                             | Ref         |                 |                |
|         | CT       | 38 (0.23)                     | 41 (0.29)                              | 1.259 (0.752–2.106) | 0.77         | 0.38023       |
|         | CC       | 6 (0.04)                      | 0 (0)                                  | 0.090 (0.005–1.611) | 5.03         | 0.02493       |
|         | T        | 276 (0.85)                    | 245 (0.86)                             | Ref         |                 |                |
|         | C        | 50 (0.15)                     | 41 (0.14)                              | 0.924 (0.591–1.445) | 0.12         | 0.72819       |
| rs1058808 HER2 | GG       | 62 (0.39)                     | 44 (0.32)                              | Ref         |                 |                |
|         | CG       | 81 (0.51)                     | 71 (0.51)                              | 1.235 (0.749–2.038) | 0.68         | 0.40828       |
|         | CC       | 17 (0.11)                     | 24 (0.17)                              | 1.989 (0.957–4.135) | 3.45         | 0.06333       |
|         | G        | 205 (0.64)                    | 159 (0.57)                             | Ref         |                 |                |
|         | C        | 115 (0.36)                    | 119 (0.43)                             | 1.334 (0.960–1.855) | 2.95         | 0.08608       |
| rs1136201 HER2 | AA       | 123 (0.76)                    | 120 (0.85)                             | Ref         |                 |                |
|         | AG       | 37 (0.23)                     | 21 (0.15)                              | 0.582 (0.322–1.051) | 3.26         | 0.07079       |
|         | GG       | 2 (0.01)                      | 0 (0)                                  | 0.205 (0.010–4.314) | 1.94         | 0.16413       |
|         | A        | 283 (0.87)                    | 261 (0.93)                             | Ref         |                 |                |
|         | G        | 41 (0.13)                     | 21 (0.07)                              | 0.555 (0.320–0.965) | 4.45         | 0.03486       |

OR 95% CI, odds ratio and 95% confidence interval. *\( p < 0.05 \) was considered significant and are depicted in bold.
Besides, HER2 gene SNP rs1058808 which did not show any association in the overall comparison demonstrated that women harboring the CC genotype were at 3.8-fold increased risk of developing colorectal cancer compared to those with the GG genotype. j"_hers1058808(c.3418C > G), also known as P1170A, is a missense variant located in exon 27 of the HER2 gene [12, 19]. Since rs1058808 and rs1136201 variants are in the coding region, they might affect the tyrosine kinase activity or structure of the protein making them unstable. HER2 gene nsSNP rs1058808 has been reported to show a negative change in Gibb’s free energy; ΔΔG value more than 1 which is −1.07 is considered to be less

### Table 3: HER1 and HER2 SNPs' genotype and allele frequencies in colorectal cancer cases and the control population based on age.

| SNP ID | Genotype   | Controls n (frequency) | Colorectal cancer n (frequency) | OR (95% CI) | \( \chi^2 \) value | \( p^* \) value |
|--------|------------|------------------------|---------------------------------|-------------|---------------------|-----------------|
| ≤58    | AA         | 22 (0.29)              | 16 (0.23)                       | Ref         |                     |                 |
|        | GA         | 46 (0.6)               | 41 (0.58)                       | 1.226 (0.568-2.645) | 0.27             | 0.60413         |
|        | GG         | 9 (0.12)               | 14 (0.2)                        | 2.139 (0.744-6.151) | 2.02             | 0.15540         |
|        | rs763317 HER1 Allele |                 |                                 |             |                     |                 |
|        | A          | 90 (0.58)              | 73 (0.51)                       | Ref         |                     |                 |
|        | G          | 64 (0.42)              | 69 (0.49)                       | 1.329 (0.840-2.104) | 1.48             | 0.22426         |
|        | TT         | 60 (0.71)              | 53 (0.74)                       | Ref         |                     |                 |
|        | CT         | 20 (0.24)              | 19 (0.26)                       | 1.075 (0.519-2.228) | 0.04             | 0.84480         |
|        | CC         | 4 (0.05)               | 0 (0)                           | 0.126 (0.007-2.388) | 3.43             | 0.06403         |
|        | rs3752651 HER1 Allele |              |                                 |             |                     |                 |
|        | T          | 140 (0.83)             | 125 (0.87)                      | Ref         |                     |                 |
|        | C          | 28 (0.17)              | 19 (0.13)                       | 0.760 (0.405-1.428) | 0.73             | 0.39268         |
|        | rs1058808 HER2 Allele |            |                                 |             |                     |                 |
|        | G          | 104 (0.63)             | 76 (0.54)                       | Ref         |                     |                 |
|        | C          | 62 (0.37)              | 64 (0.46)                       | 1.413 (0.894-2.232) | 2.19             | 0.13855         |
|        | rs1136201 HER2 Allele |          |                                 |             |                     |                 |
|        | A          | 147 (0.89)             | 133 (0.94)                      | Ref         |                     |                 |
|        | G          | 19 (0.11)              | 9 (0.06)                        | 0.524 (0.229-1.197) | 2.42             | 0.12010         |
| >58    | AA         | 21 (0.29)              | 24 (0.35)                       | Ref         |                     |                 |
|        | GA         | 36 (0.5)               | 32 (0.46)                       | 0.778 (0.366-1.654) | 0.43             | 0.51372         |
|        | GG         | 15 (0.21)              | 13 (0.19)                       | 0.758 (0.295-1.953) | 0.33             | 0.56612         |
|        | rs763317 HER1 Allele |          |                                 |             |                     |                 |
|        | A          | 78 (0.54)              | 80 (0.58)                       | Ref         |                     |                 |
|        | G          | 66 (0.46)              | 58 (0.42)                       | 0.857 (0.535-1.372) | 0.41             | 0.51996         |
|        | rs3752651 HER1 Allele |          |                                 |             |                     |                 |
|        | T          | 136 (0.86)             | 120 (0.85)                      | Ref         |                     |                 |
|        | C          | 22 (0.14)              | 22 (0.15)                       | 1.133 (0.598-2.149) | 0.15             | 0.70134         |
|        | rs1058808 HER2 Allele |          |                                 |             |                     |                 |
|        | G          | 101 (0.66)             | 83 (0.6)                        | Ref         |                     |                 |
|        | C          | 53 (0.34)              | 55 (0.4)                        | 1.263 (0.784-2.033) | 0.92             | 0.33644         |
|        | rs1136201 HER2 Allele |          |                                 |             |                     |                 |
|        | A          | 136 (0.88)             | 128 (0.91)                      | Ref         |                     |                 |
|        | G          | 22 (0.14)              | 12 (0.09)                       | 0.580 (0.276-1.219) | 2.10             | 0.14691         |

OR 95% CI, odds ratio and 95% confidence interval. *p < 0.05 was considered significant and are depicted in bold.
stable by the I-Mutant 2.0 server. The Pro1170Ala change of rs1058808 is a change from polar to nonpolar amino acid that has been reported to be deleterious according to the SIFT program [25].

Similar to our overall analysis, Han et al. did not find any correlation with genotypes of rs1058808 and rs1136201 and the occurrence of breast cancer in Korean women. However, a haplotype comprising these two nonsynonymous tagging SNPs was linked with higher HER2 expression and significantly poorer prognosis [19]. Su et al. also reported a significant association between rs1058808 and HER2 protein expression. They found that patients with CG and GG

Table 4: HER1 and HER2 SNPs’ genotype and allele frequencies in colorectal cancer cases and the control population based on gender.

| SNP ID | Genotype | Controls, n (frequency) | Colorectal cancer, n (frequency) | OR (95% CI) | $\chi^2$ value | $p*$ value |
|--------|----------|-------------------------|---------------------------------|-------------|----------------|------------|
| Male   |          |                         |                                 |             |                |            |
|        | rs763317 HER1 |                        |                                 |             |                |            |
|        | Allele   | AA 24 (0.33) 21 (0.25)   | Ref                             |             |                |            |
|        |          | GA 38 (0.52) 45 (0.54)   | 1.353 (0.654–2.802) 0.67 0.41445 |             |                |            |
|        |          | GG 11 (0.15) 18 (0.21)   | 1.870 (0.722–4.844) 1.68 0.19514 |             |                |            |
|        |          | AA 86 (0.59) 87 (0.52)   | Ref                             |             |                |            |
|        |          | G 60 (0.41) 81 (0.48)    | 1.334 (0.853–2.088) 1.60 0.20592 |             |                |            |
|        | rs3752651 HER1 | TT 51 (0.63) 60 (0.71)   | Ref                             |             |                |            |
|        |          | CT 25 (0.31) 25 (0.29)   | 0.850 (0.436–1.658) 0.23 0.63351 |             |                |            |
|        |          | CC 5 (0.06) 0 (0)        | 0.077 (0.004–1.433) 5.60 0.01798 |             |                |            |
|        | Allele   | TT 127 (0.78) 145 (0.85) | Ref                             |             |                |            |
|        |          | C 35 (0.22) 25 (0.15)    | 0.626 (0.355–1.102) 2.67 0.10247 |             |                |            |
|        | rs1058808 HER2 | GG 31 (0.38) 28 (0.33)   | Ref                             |             |                |            |
|        |          | CG 39 (0.48) 44 (0.52)   | 1.249 (0.640–2.437) 0.43 0.51412 |             |                |            |
|        |          | CC 11 (0.14) 12 (0.14)   | 1.208 (0.460–3.169) 0.15 0.70110 |             |                |            |
|        | Allele   | G 101 (0.62) 100 (0.6)   | Ref                             |             |                |            |
|        |          | C 61 (0.38) 68 (0.4)     | 1.126 (0.723–1.753) 0.28 0.59945 |             |                |            |
|        | rs1136201 HER2 | AA 61 (0.75) 67 (0.8)    | Ref                             |             |                |            |
|        |          | AG 20 (0.25) 17 (0.2)    | 0.774 (0.372–1.612) 0.47 0.49294 |             |                |            |
|        |          | GG 0 (0) 0 (0)           | 0.911 (0.018–46.620) Na 1.00000 |             |                |            |
|        | Allele   | A 142 (0.88) 151 (0.9)   | Ref                             |             |                |            |
|        |          | G 20 (0.12) 17 (0.1)     | 0.799 (0.403–1.587) 0.41 0.52159 |             |                |            |
| Female |          | AA 19 (0.25) 19 (0.34)   | Ref                             |             |                |            |
|        | rs763317 HER1 | AA 44 (0.58) 28 (0.5)    | 0.636 (0.288–1.406) 1.25 0.26263 |             |                |            |
|        |          | GG 13 (0.17) 9 (0.16)    | 0.692 (0.240–2.001) 0.46 0.49638 |             |                |            |
|        | Allele   | AA 82 (0.54) 66 (0.59)   | Ref                             |             |                |            |
|        |          | G 70 (0.46) 46 (0.41)    | 0.816 (0.498–1.337) 0.65 0.42027 |             |                |            |
|        | rs3752651 HER1 | TT 68 (0.83) 42 (0.72)   | Ref                             |             |                |            |
|        |          | CT 13 (0.16) 16 (0.28)   | 1.993 (0.872–4.555) 2.72 0.09881 |             |                |            |
|        |          | CC 1 (0.01) 0 (0)        | 0.537 (0.021–13.492) 0.61 0.43320 |             |                |            |
|        | Allele   | T 149 (0.91) 100 (0.86)  | Ref                             |             |                |            |
|        |          | C 15 (0.09) 16 (0.14)    | 1.589 (0.752–3.360) 1.49 0.22221 |             |                |            |
|        | rs1058808 HER2 | GG 31 (0.39) 16 (0.29)   | Ref                             |             |                |            |
|        |          | CG 42 (0.53) 27 (0.49)   | 1.246 (0.575–2.699) 0.31 0.57754 |             |                |            |
|        |          | CC 6 (0.08) 12 (0.22)    | 3.875 (1.226–12.248) 5.65 0.01746 |             |                |            |
|        | Allele   | G 104 (0.66) 59 (0.54)   | Ref                             |             |                |            |
|        |          | C 54 (0.34) 51 (0.46)    | 1.665 (1.011–2.741) 4.04 0.04439 |             |                |            |
|        | rs1136201 HER2 | AA 62 (0.77) 53 (0.93)   | Ref                             |             |                |            |
|        |          | AG 17 (0.21) 4 (0.07)    | 0.275 (0.087–0.869) 5.33 0.02093 |             |                |            |
|        |          | GG 2 (0.02) 0 (0)        | 0.234 (0.011–4.974) 1.69 0.19425 |             |                |            |
|        | Allele   | A 141 (0.89) 110 (0.96)  | Ref                             |             |                |            |
|        |          | G 21 (0.13) 4 (0.04)     | 0.244 (0.081–0.732) 7.26 0.00705 |             |                |            |

OR 95% CI, odds ratio and 95% confidence interval; na, not analyzable. * $p < 0.05$ was considered significant and are depicted in bold.
genotypes of rs1058808 demonstrated higher HER2 protein expression relative to those having the CC genotype (p < 0.01) [26]. The mechanism related to the higher HER2 protein expression with genetic variants needs further investigations. Conflicting reports pertaining to the association of rs1058808 and rs1136201 with different cancer types have been reported [11, 13, 27–29]. In view of the involvement of HER1 and HER2 in several malignancies such as breast cancer, ovarian cancer, non-small-cell lung cancer, head and neck cancers, gastric cancer, and hepatocellular carcinoma, it would be interesting to examine the association of SNPs tested in this study with these cancers [30, 31].

Despite significant findings, the drawback of our study is that the sample size is relatively small and from a single hospital in the capital city Riyadh which receives patients from all over the country but may not represent the entire Saudi population. Additionally, since consanguinity is common in Saudi Arabia, it may have introduced some bias in our results. Another limitation of our study is that we took a simplistic view and performed an association of individual SNP with CRC; however, haplotype linkage disequilibrium analysis together with additional SNPs on same chromosome might provide broader insights into the role of HER1 and HER2 variants in the causation of the disease.

In conclusion, our preliminary analysis on selected SNPs in HER1 and HER2 genes suggests a statistically significant association of rs3752651, rs1058808, and rs1136201 with colorectal cancer in a Saudi population. These associations were gender specific and not related to the age of onset of the disease. The rs3752651 in men and rs1136201 in women showed protective association, while rs1058808 increases the risk of colorectal cancers in women. Although our results are significant, due to the small sample size, it should be validated in a larger cohort of diverse ethnicities along with haplotype linkage analysis before utilizing these SNPs as screening markers for colorectal cancers.

Data Availability
All data used to support the findings of this study are included within the article.

Conflicts of Interest
The authors declare no conflicts of interest.

Acknowledgments
The authors are grateful to the Deanship of Scientific Research, King Saud University, for funding through the Vice Deanship of Scientific Research Chairs.

References
[1] F. Caputo, C. Santini, C. Bardasi et al., "BRAF-mutated colorectal cancer: clinical and molecular insights," International Journal of Molecular Sciences, vol. 20, no. 21, p. 5369, 2019.
[2] E. Dekker, P. J. Tanis, J. L. A. Vleugels, P. M. Kasi, and M. B. Wallace, "Colorectal cancer," The Lancet, vol. 394, no. 10207, pp. 1467–1480, 2019.
[3] J. Ferlay, “Global cancer Observatory: cancer today. Lyon, France: international agency for Research on cancer,” 2018, https://gco.iarc.fr/today.
[4] E. R. Fearon and B. Vogelstein, "A genetic model for colorectal tumorigenesis," Cell, vol. 61, no. 5, pp. 759–767, 1990.
[5] A. S. Sameer, "Colorectal cancer: molecular mutations and polymorphisms," Frontiers in Oncology, vol. 3, p. 114, 2013.
[6] N. S. Sameer, M. Z. Banday, and S. Nissar, "Mutations and polymorphisms: what is the difference?", in Genetic Polymorphism and Cancer Susceptibility, A. S. Sameer, M. Z. Banday, and S. Nissar, Eds., Springer Singapore, Singapore, pp. 1–21, 2021.
[7] B. S. Shastry, "SNP alleles in human disease and evolution," Journal of Human Genetics, vol. 47, no. 11, pp. 561–566, 2002.
[8] S. Sunyaev, "Prediction of deleterious human alleles," Human Molecular Genetics, vol. 10, no. 6, pp. 591–597, 2001.
[9] Z. Koveitypourg, F. Panahi, M. Vakilian et al., "Signaling pathways involved in colorectal cancer progression," Cell & Bioscience, vol. 9, no. 1, p. 97, 2019.
[10] E. M. Poole, K Curtin, I. Hsu et al., "Genetic variability in EGFR, Src and HER2 and risk of colorectal adenoma and cancer," International journal of molecular epidemiology and genetics, vol. 2, no. 4, pp. 300–315, 2011.
[11] J. P. Breyer, M. E. Sanders, D. C. Airey et al., "Heritable variation of ERBB2 and breast cancer risk," Cancer Epidemiology Biomarkers & Prevention, vol. 18, no. 4, pp. 1252–1258, 2009.
[12] P. R. Benusiglio, F. Lesueur, C. Luccarini et al., "Common ERBB2 polymorphisms and risk of breast cancer in a white British population: a case-control study," Breast Cancer Research, vol. 7, no. 2, pp. R204–R209, 2005.
[13] U. H. Jo, S. G. L. Han, J. H. Seo et al., "The genetic polymorphisms of HER-2 and the risk of lung cancer in a Korean population," BMC Cancer, vol. 8, no. 1, p. 359, 2008.
[14] R. Millikan, A. Eaton, K. Worley et al., "HER2 codon 655 polymorphism and risk of breast cancer in African Americans and whites," Breast Cancer Research and Treatment, vol. 79, no. 3, pp. 355–364, 2003.
[15] S. Santhananam, Polymorphism and Overexpression of HER2/neu Among Ovarian Carcinoma Women from Tiruchirapalli, p. 288, Archives of gynecology and obstetrics, Chennai, India, 2013.
[16] C. Liu, X. Xu, and Y. Zhou, "Association between EGFR polymorphisms and the risk of lung cancer," International Journal of Clinical and Experimental Pathology, vol. 8, no. 11, pp. 15245–15249, 2015.
[17] R. Hasan, D. Bhatt, S. Khan et al., "Frequency of I655V SNP of HER-2/neu in colorectal cancer: a study from India," 3 Biotech, vol. 9, no. 1, p. 11, 2019.
[18] J. A. McKay, J. F. Loane, V. G. Ross et al., "C-erbB-2 is not a major factor in the development of colorectal cancer," British Journal of Cancer, vol. 86, no. 4, pp. 568–573, 2002.
[19] W. Han, "A haplotype analysis of HER-2 gene polymorphisms: association with breast cancer risk. HER-2 protein expression in the tumor, and disease recurrence in Korea," Clinical Cancer Research, vol. 11, no. 13, pp. 4775–4778, 2005.
[20] M. A. el-Hazmi, A. R. Al-Swailem, A. S. Warzy, A. M. Al-Swailem, R. Sulaimani, and A. A. Al-Meshari, "Consanguinity among the Saudi Arabian population," Journal of Medical Genetics, vol. 32, no. 8, pp. 623–626, 1995.
[21] N. Prenzel, O. M. Fischer, S. Streit, S. Hart, and A. Ullrich, "The epidermal growth factor receptor family as a central element for cellular signal transduction and diversification," Endocrine-Related Cancer, vol. 8, no. 1, pp. 11–31, 2001.
[22] B. Li, W. Zhao, J. Li et al., "Effect of epidermal growth factor receptor gene polymorphisms on prognosis in glioma patients," *Oncotarget*, vol. 7, no. 39, pp. 63054–63064, 2016.

[23] F. C. de Almeida, B. K. Banin Hirata, C. B. Ariza et al., “HER2Ile655Val polymorphism is negatively associated with breast cancer susceptibility,” *Journal of Clinical Laboratory Analysis*, vol. 32, no. 6, Article ID e22406, 2018.

[24] S. E. Nelson, M. N. Gould, J. M. Hampton, and A. Trentham-Dietz, “A case-control study of the HER2 Ile655Val polymorphism in relation to risk of invasive breast cancer,” *Breast Cancer Research*, vol. 7, no. 3, pp. R357–R364, 2005.

[25] R. Rajasekaran, C. George Priya Doss, C. Sudandiradoss, K. Ramanathan, R. Purohit, and R. Sethumadhavan, “Effect of deleterious nsSNP on the HER2 receptor based on stability and binding affinity with herceptin: a computational approach,” *Comptes Rendus Biologies*, vol. 331, no. 6, pp. 409–417, 2008.

[26] Y. Su, Y. Jiang, S. Sun et al., “Effects of HER2 genetic polymorphisms on its protein expression in breast cancer,” *Cancer Epidemiology*, vol. 39, no. 6, pp. 1123–1127, 2015.

[27] D. Xie, "Population-based, case-control study of HER2 genetic polymorphism and breast cancer risk," *Journal of the National Cancer Institute*, vol. 92, no. 5, pp. 412–417, 2000.

[28] Y. Gao, X. Tang, J. Cao et al., "The effect of HER2 single nucleotide polymorphisms on cervical cancer susceptibility and survival in a Chinese population," *Journal of Cancer*, vol. 10, no. 2, pp. 378–387, 2019.

[29] B. Frank, K. Hemminki, M. Wirtenberger et al., “The rare ERBB2 variant Ile654Val is associated with an increased familial breast cancer risk,” *Carcinogenesis*, vol. 26, no. 3, pp. 643–647, 2005.

[30] Z. Wang, "ErbB receptors and cancer," *Methods in Molecular Biology*, vol. 1652, pp. 3–35, 2017.

[31] J.-H. Shi, W.-Z. Guo, Y. Jin et al., “Recognition of HER2 expression in hepatocellular carcinoma and its significance in postoperative tumor recurrence,” *Cancer Medicine*, vol. 8, no. 3, pp. 1269–1278, 2019.